Eisai Co., Ltd.
4523----
Eisai Co., Ltd. (4523)
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
News
- Japan Corporate News · 14 hours ago
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
- Press Releases · 17 hours ago
AWS Announces General Availability of AWS HealthOmics in the Asia Pacific (Tokyo) Region
- TradingView · Jul 20 at 05:14 PM
Weekly Recap: LEQEMBI IQLIK FDA approval and lecanemab SC bioequivalence
- Simplywall · Jul 20 at 04:13 PM
Does Real‑World Leqembi Iqlik Data And At‑Home Use Shift The Bull Case For Eisai (TSE:4523)?
- Japan Corporate News · Jul 17 at 06:16 PM
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
- Japan Corporate News · Jul 15 at 01:50 PM
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
